Uncertainties about the quality of medical products globally: lessons from multidisciplinary research

Kingori, Patricia; Grietens, Koen Peeters; Abimbola, Seye; Ravinetto, Raffaella

doi:10.1136/bmjgh-2023-012902

Cited by 16 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Quality care requires a well-trained health care workforce, sustainable availability of accurate diagnostics, reliable infrastructure and medication supplies and should be monitored in an ongoing process of quality improvement (Figure 4). The quality of medications, especially in LMICs, may be an additional barrier to successful management of CKD (Kingori et al, 2023). Regulation and monitoring of drug Essential Medication List (Table 1).…”

Section: Health Systemsmentioning

confidence: 99%

Mind the gap in kidney care: Translating what we know into what we do

Luyckx,

Tuttle,

Abdellatif

et al. 2024

Journal of Renal Care

View full text Add to dashboard Cite

Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.

show abstract

Section: Health Systemsmentioning

confidence: 99%

Mind the gap in kidney care: Translating what we know into what we do

Luyckx,

Tuttle,

Abdellatif

et al. 2024

Journal of Renal Care

View full text Add to dashboard Cite

show abstract

“…systemic policy approach enriched and directed by interdisciplinary research across various fields. 8,9…”

Section: Disclosuresmentioning

confidence: 99%

“… 6 , 7 These outbreaks serve as a reminder of the difficulties faced in less resourced nations for improvement in regulation, enforcement, or strict implementation of quality control procedures in the pharmaceutical industry. 8 , 9 Compromises within the pharmaceutical supply chain lead to a proliferation of substandard and falsified (SF) medications. This emphasizes the necessity to evaluate various perspectives through investigations into the structural, political, economic, and ethical elements that shape the quality and utilization of medical products.…”

mentioning

confidence: 99%

“…There is a need for international expansion of formal training on SF medical products to address systemic inadequacies and emphasize the integration of public health education within pharmaceutical training and strengthen the capacity for pharmacists and physicians together to play a pivotal role in safeguarding public health. 8 – 10 The intricate interconnection of social and ethical determinants in the issue of SF medicinal products underscores that mere technical interventions are insufficient; instead, it necessitates a comprehensive systemic policy approach enriched and directed by interdisciplinary research across various fields. 8 , 9 …”

mentioning

confidence: 99%

“… 8 – 10 The intricate interconnection of social and ethical determinants in the issue of SF medicinal products underscores that mere technical interventions are insufficient; instead, it necessitates a comprehensive systemic policy approach enriched and directed by interdisciplinary research across various fields. 8 , 9 …”

mentioning

confidence: 99%

See 2 more Smart Citations

Sudden Spurt in Pediatric Patients with AKI in Uzbekistan: A Call for International Drug Quality Control and Pharmaceutical Legislation

Murtalibova,

Sethi,

Raina

et al. 2023

Kidney360

View full text Add to dashboard Cite

show abstract

Mind the gap in kidney care: translating what we know into what we do

Luyckx,

Tuttle,

Abdellatif

et al. 2024

Clin Exp Nephrol

View full text Add to dashboard Cite

Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages, it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.

show abstract

Uncertainties about the quality of medical products globally: lessons from multidisciplinary research

Cited by 16 publications

References 19 publications

Mind the gap in kidney care: Translating what we know into what we do

Mind the gap in kidney care: Translating what we know into what we do

Sudden Spurt in Pediatric Patients with AKI in Uzbekistan: A Call for International Drug Quality Control and Pharmaceutical Legislation

Mind the gap in kidney care: translating what we know into what we do

Contact Info

Product

Resources

About